Replies to post #44855 on Langlui's Big Board and Options Plays

[3xBuBu]

Per Official site:
http://www.russell.com/indexes/membership/reconstitution/Reconstitution_changes.aspx
Russell Reconstitution
Preliminary additions and deletions

[dc_350]

Your Addition and Deletion postings all contain the same stocks...just sorted differently....

[glassy]

AVANIR Pharmaceuticals Announces It Has Been Added to the Russell 3000(R) Index
Jun 29, 2009 1:00:00 PM
Copyright Business Wire 2009


Email Story Discuss on ZenoBank

View Additional ProfilesALISO VIEJO, Calif.--(BUSINESS WIRE)-- AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) announced that it has been added to the broad-market Russell 3000 Index, an investment tool comprised of 3,000 of the country's largest and most liquid stocks. Russell Investments reconstituted its Russell 3000 Index on June 26, 2009 with the 3,000 largest U.S. stocks by market capitalization as of the end of May.

AVANIR's membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000 Index as well as the appropriate growth and value indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. A listing on such indexes often increases a stock's price and liquidity, since index funds and related mutual funds must buy shares

[glassy]

Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response
Jun 30, 2009 6:30:00 AM
2009 GlobeNewswire, Inc.



View Additional ProfilesSAN DIEGO, June 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. The company is ready to advance directly to large-scale cGMP manufacturing of the vaccine for human clinical trials, subject to securing external funding for this program.

"Our DNA vaccine technology offers an innovative approach to dealing with pandemics," said Vijay B. Samant, President and Chief Executive Officer of Vical. "The speed of our platform both in development and manufacturing was demonstrated by our rapid completion of vaccine production and successful immunogenicity testing in animals while conventional vaccine manufacturers are still working toward production of their initial supply of H1 vaccine. We are encouraged by these compelling data with our Vaxfectin(r)-formulated DNA vaccine and we look forward to advancing to human clinical trials as soon as possible."

Vical's plasmid DNA vaccine contained the H1 hemagglutinin gene sequence provided by the U.S. Centers for Disease Control and Prevention (CDC) for the A/H1N1 influenza strain selected on April 30. The preclinical vaccine was produced by May 11 and animal testing began on May 15. In two parallel animal studies, one in mice and one in rabbits, vaccine was administered on Day 0 and Day 21, a standard regimen for pandemic influenza vaccines. Sera collected on Day 21, after a single dose of vaccine, showed clear increases over baseline hemagglutination inhibition (HI) titers in 100% of the animals, and HI titers above the protection threshold in 88% of the mice and 75% of the rabbits. Sera collected on Day 35, two weeks after the second dose, showed HI titers well above the protection threshold in 100% of the animals, ranging from 320 to 2,560 (geometric mean titer = 987) in the mice, and from 640 to 2,560 (geometric mean titer = 1,522) in the rabbits. The HI assay measures a vaccine's ability to prevent viruses from binding to cells, and HI titers of 40 or more are accepted as the threshold for potential protection against influenza viruses. The vaccine encoded H1 hemagglutinin from the swine-origin A/California/04/09 wild-type influenza virus. Vical ran the HI assay against the swine-origin A/California/07/09 x-179a reassortant influenza virus obtained from the CDC.